Skip to main content
Industry News
Early data: Remdesivir may aid COVID-19 recovery

Many patients with severe COVID-19 who received daily infusions of Gilead Sciences' antiviral drug remdesivir experienced rapid recoveries, and almost all were discharged in less than one week, according to infectious disease specialist Kathleen Mullane, who is supervising the research at the University of Chicago Medicine. The comments were made during an internal presentation, and the institution said "drawing any conclusions at this point is premature and scientifically unsound."

Full Story: